A New Proposal for OFCC-based Instrumentation Amplifier

This contribution puts forward a new voltage mode instrumentation amplifier (VMIA) based on operational floating current conveyor (OFCC). It presents high impedance at input terminals and provides output at low impedance making the proposal ideal for voltage mode operation. The proposed VMIA architecture has two stages - the first stage comprises of two OFCCs to sense input voltages and coverts the voltage difference to current while the second stage has single OFCC that converts the current to voltage. In addition it employs two resistors to provide gain and imposes no condition on the values of resistors.  The behavior of the proposed structure is also analyzed for OFCC non idealities namely finite transimpedance and tracking error. The proposal is verified through SPICE simulations using CMOS based schematic of OFCC. Experimental results, by bread boarding it using commercially available IC AD844, are also included

Realization of OFCC based transimpedance mode instrumentation amplifier

The paper presents an instrumentation amplifier suitable for amplifying the current source transducer signals. It provides a voltage output. It has a high gain, common mode rejection ratio and gain independent bandwidth. It uses three Operational Floating Current Conveyors (OFCCs) and four resistors. The effect of nonidealities of OFCC on performance of proposed transimpedance instrumentation amplifier (TIA) is also analyzed. The proposal has been verified through SPICE simulations using CMOS based schematicThe paper presents an instrumentation amplifier suitable for amplifying the current source transducer signals. It provides a voltage output. It has a high gain, common mode rejection ratio and gain independent bandwidth. It uses three operational floating current conveyors (OFCCs) and four resistors. The effect of nonidealities of OFCC on performance of proposed transimpedance instrumentation amplifier (TIA) is also analyzed. The proposal has been verified through SPICE simulations using CMOS based schematic

Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support-free days in patients hospitalized with COVID-19

IMPORTANCE Overactivation of the renin-angiotensin system (RAS) may contribute to poor clinical outcomes in patients with COVID-19. Objective To determine whether angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) initiation improves outcomes in patients hospitalized for COVID-19. DESIGN, SETTING, AND PARTICIPANTS In an ongoing, adaptive platform randomized clinical trial, 721 critically ill and 58 non–critically ill hospitalized adults were randomized to receive an RAS inhibitor or control between March 16, 2021, and February 25, 2022, at 69 sites in 7 countries (final follow-up on June 1, 2022). INTERVENTIONS Patients were randomized to receive open-label initiation of an ACE inhibitor (n = 257), ARB (n = 248), ARB in combination with DMX-200 (a chemokine receptor-2 inhibitor; n = 10), or no RAS inhibitor (control; n = 264) for up to 10 days. MAIN OUTCOMES AND MEASURES The primary outcome was organ support–free days, a composite of hospital survival and days alive without cardiovascular or respiratory organ support through 21 days. The primary analysis was a bayesian cumulative logistic model. Odds ratios (ORs) greater than 1 represent improved outcomes. RESULTS On February 25, 2022, enrollment was discontinued due to safety concerns. Among 679 critically ill patients with available primary outcome data, the median age was 56 years and 239 participants (35.2%) were women. Median (IQR) organ support–free days among critically ill patients was 10 (–1 to 16) in the ACE inhibitor group (n = 231), 8 (–1 to 17) in the ARB group (n = 217), and 12 (0 to 17) in the control group (n = 231) (median adjusted odds ratios of 0.77 [95% bayesian credible interval, 0.58-1.06] for improvement for ACE inhibitor and 0.76 [95% credible interval, 0.56-1.05] for ARB compared with control). The posterior probabilities that ACE inhibitors and ARBs worsened organ support–free days compared with control were 94.9% and 95.4%, respectively. Hospital survival occurred in 166 of 231 critically ill participants (71.9%) in the ACE inhibitor group, 152 of 217 (70.0%) in the ARB group, and 182 of 231 (78.8%) in the control group (posterior probabilities that ACE inhibitor and ARB worsened hospital survival compared with control were 95.3% and 98.1%, respectively). CONCLUSIONS AND RELEVANCE In this trial, among critically ill adults with COVID-19, initiation of an ACE inhibitor or ARB did not improve, and likely worsened, clinical outcomes. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT0273570

Single-Input Four-Output Current Mode Filter Using Operational Floating Current Conveyor

This paper presents operational floating current conveyor (OFCC) based single input four output current mode filter. It employs only three OFCCs and two grounded capacitors and resistors each. The MOS based grounded resistors implementation is used, which adds feature of electronic tunability to the filter parameters. The filter also enjoys low component spread and low sensitivity performance. The effect of finite transimpedance and parasites of OFCC on the proposed circuit is also analyzed. The functionality of the proposed circuit is demonstrated through SPICE simulations using 0.5 µm CMOS process model provided by MOSIS (AGILENT)